Respivert Limited

Topivert Pharma Limited

Chroma Therapeutics Limited

Jonathan Gareth Williams

Stuart Thomas Onions

Peter John Murray

John King-Underwood

Catherine Elisabeth Charron

Kazuhiro Ito

Peter Strong

William Garth Rapeport

Simon Christopher Hirst

David Michel Adrien Taddei

Kevin Joly

George Hardy

Stephen Thom

Matthew Colin Thor Fyfe

Alistair Ian Longshaw

Euan Alexander Fraser Fordyce

David Festus Charles Moffat

Stephen John Davies

Lorna Duffy

Michael Hugh Charlton

Daniel Hamza

Claire Anne Marie Cariou

Ildiko Buck

David Michael Adrien Taddei

Hayley Tegan Angela Watson

Ito Kazuhiro

Stephen Malcolm Thom

Catherine Elizabeth Charron

The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).

Respiratory formulations and compounds for use therein

There is provided inter alia a compound of formula (I): wherein R, J, Ar, L, X, Rand Rare as defined in the specification, for use in the treatment of inflammatory disorders.

P38 MAP kinase inhibitors

There are provided inter alia compounds of formula (I) wherein R, R, R, R, R, L, X, Rand Rare as defined in the description for use in the treatment of inflammatory diseases.

Pyrazole P38 map kinase inhibitors

Pyrazole p38 map kinase inhibitors

There are provided compounds of formula I, 

Pyrazolyl-ureas as kinase inhibitors

Pyrazole derivatives as p38 MAP inhibitors

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

P38MAP kinase inhibitors

There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis. 

There are provided inter alia compounds of formula (I) wherein R, Ar, L, X, Rand Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I). 

P38MAP kinase inhibitor

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

Growing community of inventors

Nottingham, United Kingdom

Jonathan Gareth Williams